Similar articles

• Methylphenidate for attention-deficit/hyperactivity disorder: The longest debate.

  Levy F. Levy F. Aust N Z J Psychiatry. 2016 Jul;50(7):616-7. doi: 10.1177/0004867416643390. Epub 2016 Apr 11. Aust N Z J Psychiatry. 2016. PMID: 27066820 No abstract available.
• [Methylphenidate (Ritalin) treatment in attention deficit hyperactivity disorder].

  Shalev R, Gross-Tsur V. Shalev R, et al. Harefuah. 1997 May 1;132(9):672-5. Harefuah. 1997. PMID: 9225587 Review. Hebrew. No abstract available.
• Is the evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder flawed?

  Hoekstra PJ, Buitelaar JK. Hoekstra PJ, et al. Eur Child Adolesc Psychiatry. 2016 Apr;25(4):339-40. doi: 10.1007/s00787-016-0845-2. Eur Child Adolesc Psychiatry. 2016. PMID: 27021055 No abstract available.
• Attention-deficit hyperactivity disorder, methylphenidate, and primary encopresis.

  Golubchik P, Weizman A. Golubchik P, et al. Psychosomatics. 2009 Mar-Apr;50(2):178. doi: 10.1176/appi.psy.50.2.178. Psychosomatics. 2009. PMID: 19377031 No abstract available.
• [Attention deficit disorder with hyperactivity (ADHD). Continuing symptom control with medium term methylphenidate treatment].

  Oberpichler-Schwenk H. Oberpichler-Schwenk H. Med Monatsschr Pharm. 2006 Nov;29(11):415-6. Med Monatsschr Pharm. 2006. PMID: 17131689 Review. German. No abstract available.